Skip to content
HowShorted

Sana Biotechnology, Inc. short interest in 2023

In 2023, Sana Biotechnology, Inc.'s disclosed short interest ran from 13.92% of shares outstanding on 13 Jan 2023 to 11.19% on 29 Dec 2023, a change of -2.73 percentage points. The year's high was 15.86% on 31 Mar 2023 and its low 10.56% on 30 Nov 2023, averaging 13.26% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 39.00 days on 14 Jul 2023. Full history: Sana Biotechnology, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Sana Biotechnology, Inc. in 2023

2023 in figures

Start of year
13.92% (13 Jan 2023)
End of year
11.19% (29 Dec 2023)
Change
-2.73 pp
High
15.86% (31 Mar 2023)
Low
10.56% (30 Nov 2023)
Average
13.26%
Highest days to cover
39.00 (14 Jul 2023)
SEC filings marked
8

Every report in 2023

Sana Biotechnology, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202313.92%24.73
31 Jan 202313.63%27.57
15 Feb 202314.15%33.51
28 Feb 202314.60%27.72
15 Mar 202315.68%28.75
31 Mar 202315.86%30.6110-K filed, results (8-K)
14 Apr 202315.44%17.18
28 Apr 202314.75%21.61
15 May 202314.76%17.9510-Q filed, results (8-K)
31 May 202314.78%18.02
15 Jun 202314.36%23.59
30 Jun 202314.54%17.01
14 Jul 202314.33%39.00
31 Jul 202311.93%22.96
15 Aug 202311.82%28.4010-Q filed, results (8-K)
31 Aug 202311.89%36.76
15 Sep 202311.46%19.05
29 Sep 202312.42%20.90
13 Oct 202313.10%17.98
31 Oct 202311.35%16.09
15 Nov 202310.96%14.3210-Q filed, results (8-K)
30 Nov 202310.56%17.23
15 Dec 202310.77%12.79
29 Dec 202311.19%15.01

See also: Sana Biotechnology, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.